{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-024969","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.914927+00:00","generated_at":"2026-06-11T01:07:15.075174+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zevra sets $10M AZSTARYS milestone for 2023; merger with Acer announced","bullets":["Next AZSTARYS sales milestone is $10.0M; expected to be achieved in FY 2023 per current prescription trends.","Zevra announced merger with Acer Therapeutics; Acer will become a wholly owned subsidiary upon shareholder approval.","Zevra hosted a conference call on Aug 31, 2023 to provide supplemental information on the merger.","Employee communication from interim CEO Christal Mickle distributed to Acer staff on Aug 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-024969","json":"https://secwatch.observer/filing/0001437749-23-024969.json","markdown":"https://secwatch.observer/filing/0001437749-23-024969.md","text":"https://secwatch.observer/filing/0001437749-23-024969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923024969/0001437749-23-024969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923024969/zvra20230831d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:07:15.075174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}